Trial Profile
Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 01 Mar 2024 Planned End Date changed from 1 Dec 2023 to 20 Feb 2031.
- 01 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 20 Feb 2024.
- 12 Dec 2023 Results (n=28), assessing the efficacy and tolerability in patients in MZL patients presented at the 65th American Society of Hematology Annual Meeting and Exposition